Boehringer Ingelheim has returned to Kyowa Kirin for a 640 million euro ($743 million) deal for a preclinical program the German pharma hopes will offer a new autoimmune disease option. | Boehringer ...

The licensed small molecule program aims to address significant unmet needs forautoimmune diseases. Programadds toBoehringer’s pipeline and its ...

The licensed small molecule program aims to address significant unmet needs for autoimmune diseases.

Boehringer Ingelheim Pharma GmbH & Co. KG has discovered son of sevenless homolog 1 (SOS1) inhibitors potentially useful for the treatment of cancer.

Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed ...

Ingelheim. Hoch: Eine SchlüsselindustrieMit einem Festakt im Beisein von Clemens Hoch, Wissenschaftsminister in Rheinland-Pfalz, hat das Pharmaunternehmen Boehringer Ingelheim ihre neue NHP-Anlage in ...

Boehringer Ingelheim has expanded its oncology pipeline with the acquisition of a preclinical small molecule program from Accent Therapeutics. The asset, which targets tumors characterized by high ...

More than 10 years after bringing one of the first idiopathic pulmonary fibrosis (IPF) drugs to market, Boehringer Ingelheim is freshening up its leadership in the rare lung disease space with a newly ...

Jascayd is the first new IPF therapy approved in over 10 years, addressing a rare and serious disease with limited treatments. FDA approval was based on Phase III trials showing reduced FVC decline ...

The FDA has approved Boehringer Ingelheim’s twice-daily pill nerandomilast for the treatment of idiopathic pulmonary fibrosis. The drug will carry the brand name Jascayd. According to the FDA’s ...

Privately-held US biopharma Accent Therapeutics has announced an asset purchase agreement with Germany’s Boehringer Ingelheim for a pre-clinical, potentially first-in-class small molecule program. The ...